National Health (Listed Drugs on F1 or F2) Determination 2021

The Determination rests on a few tightly circumscribed legal concepts that appear in the text.

• Designation by reference. The operative mechanism is designation by reference to the Act. Section 6 states that the items in Schedule 1 are "on F1" for the purposes of subsection 85AB(1) of the Act; section 7 does the same for Schedule 2 and F2. The instrument therefore operates only insofar as subsection 85AB(1) requires or permits a list of drugs to be specified by statutory instrument. The Determination does not define "F1" or "F2" itself; it imports the categories from the Act by reference.

• Lists as authoritative source. The Schedules are the primary content of the instrument. Schedule 1 (F1) and Schedule 2 (F2) present entries as single-line items or descriptive formulations. The instrument treats the text of these Schedules as authoritative for the purposes of subsection 85AB(1) (ss 6-7). That means that the legal designation turns on the literal entries in the Schedules, not on external labels or market names not reflected in the Schedules.

• Compilation and amendment metadata. The instrument is presented as a registered compilation (Compilation No. 53) with a compilation date (1 March 2026) and a statement "Includes amendments: F2026L00179." The endnotes provide the amending instrument register entries and commencement dates (Endnote 3) and list the amendment history by provision (Endnote 4). The presence of numerous amendment determinations in the legislation history confirms that the lists are updated frequently by separate amending determinations rather than by a single consolidated act.

• Narrow drafting choices. The only defined term in the instrument (s 5) is "Act," which is defined to mean the National Health Act 1953. No definitions are provided of "drug", "formulation", "product", "brand", "strength", "presentation" or "schedule entry." The instrument therefore adopts a plain-list approach: the Schedule entries themselves carry the classification weight.

• Non‑regulatory instrument character. The Determination does not set out procedural obligations, fees, or offences, nor does it create administrative rights or duties beyond the classification. It is an instrument that determines content for use elsewhere in the Act. The technical operation is to populate categories (F1, F2) that the Act references. The bulk of the work is therefore the Schedule text.

These concepts combine to yield an instrument whose legal effect is discrete: it provides the named universe of items that are deemed to be "on F1" or "on F2" for the single statutory reference in subsection 85AB(1). The Determination’s operational significance is therefore interstitial: it is meaningful only together with the Act’s provisions that attach consequences to those categories.

The Determination’s direct textual effect is to classify named drugs as "on F1" or "on F2" under subsection 85AB(1) of the National Health Act 1953. Who is affected in practice depends on the role that the Act gives to those classifications. The instrument itself does not specify downstream entitlements or obligations, but it is reasonable and textually supportable to identify categories of stakeholders for whom the classification will be consequential because their statutory entitlements, procurement, reimbursement, formularies or regulatory positions are commonly linked to such classifications in health law and policy frameworks.

• Persons and entities whose rights or obligations in the Act depend on an item being "on F1" or "on F2". The Determination is addressed to the legal operation of subsection 85AB(1). Any person whose statutory status under the Act depends on whether a medicine is on F1 or F2 will be affected by entries in these Schedules (see ss 6-7). The instrument itself does not enumerate those statutory consequences; to identify the precise legal effect the reader must consult s 85AB(1) and related provisions of the Act.

• Suppliers, manufacturers and sponsors. Entities that manufacture, supply or sponsor products listed in Schedule 1 or Schedule 2 should treat the listing as legally material. The listing is the declared legal classification for those products for the purposes of subsection 85AB(1) (ss 6-7). Changes to the Schedules (see Endnote 3 and Endnote 4) may alter how an individual product is classified.

• Prescribers and dispensers. Clinicians, pharmacists and dispensing authorities who rely on statutory classification for funding, prescribing rules or supply pathways must monitor the schedules. Although the Determination does not itself set prescribing limits, it creates the authoritative list used by the Act; therefore, professionals relying on statutory lists for compliance or reimbursement should incorporate the Schedules into their compliance processes.

• Payers and program administrators. Government departments, purchasing agencies and administrators who implement funding or subsidy schemes that reference the Act’s categories must track amendments to the Schedules. The legislation history shows frequent monthly updates through separate amending determinations (Endnote 3), which implies ongoing operational work for administrators who reconcile policy rules with the current lists.

• Patients and consumers. Individuals who receive medicines, particularly for high-cost or specialised therapies, will be indirectly affected to the extent their access, subsidy or treatment pathway depends on the status of a product under the Act. The Determination’s lists determine the legal classification used by the Act, and therefore may bear on entitlements attached to those classes.

• Legal and compliance advisers. Because the instrument is a statutory list that is frequently amended (Endnote 3), corporate counsel, procurement teams and compliance officers in health-care businesses and public agencies will be affected by the need to monitor the Register and the instrument’s amendment history to ensure accurate classification histories.

The instrument’s endnotes demonstrate active management: the legislation history records more than 60 amendment determinations between March 2021 and March 2026 (Endnote 3). That frequency affects the practical burden on affected stakeholders: classification is not static. The Determination therefore imposes an information‑maintenance cost on parties who need to stay aligned with the current schedules, even though the instrument itself creates no express reporting or compliance duties.

The Determination, read on its face, does not create standalone duties, rights, offences or regulatory processes. Its legal function is declaratory: it populates the categories "F1" and "F2" as referenced by subsection 85AB(1) of the National Health Act 1953. The operative provisions that impose duties or confer rights are contained in the parent Act, not in this Determination. The Determination’s Clauses 6 and 7 therefore operate as the factual predicate for any legal consequence that the Act attaches to being "on F1" or "on F2."

• What the Determination does impose. The instrument imposes no positive obligations on private parties in its text. It does not require action, registration, reporting or payment by a named party. Instead, the Determination defines which pharmaceutical items will be treated as within particular legal categories for the Act’s purposes (ss 6-7, Schedules).

• What the Determination creates indirectly. Because the instrument specifies the items "on F1" and "on F2," it determines the set of products to which any statutory duties, entitlements or administrative rules in the Act apply. Any duty or right in the Act that is triggered by, or depends on, that categorisation will apply to the listed products as a legal consequence of this instrument. The Determination itself does not restate these duties; the reader must consult subsection 85AB(1) and related statutory provisions to identify the specific duties and rights that flow from the classification.

• Limited definitional content. The Determination contains only a single short definitions clause (s 5) defining "Act." No other definitions are provided to clarify how Schedule entries are to be read (for example, no express rule on whether an entry includes all strengths, all formulations, generic equivalents or brand variants). That absence means interpretation of the Schedule entries will fall to ordinary statutory interpretation principles and whatever interpretive or administrative practice the relevant decision-maker applies under the Act.

• Administrative burden for compliance. Although the instrument imposes no textual duties, it creates a compliance burden in practice for parties who must ensure their internal formularies, procurement, supply and prescribing processes reflect the current Schedules. The endnotes show frequent amendments and separate amending determinations (Endnote 3), which increases the operational duty to monitor and update systems.

• No enforcement provisions in the Determination. There are no penalty provisions, inspection powers or enforcement mechanisms in the Determination itself. Any enforcement or sanctioning powers would be found in the Act or other linked instruments and statutes.

In short: the Determination creates the factual universe for any statutory duties and rights in the National Health Act 1953 that depend on the categories F1 and F2. Those duties and rights are not contained in the Determination. Practitioners must therefore read the Determination together with subsection 85AB(1) and other provisions of the Act to determine the concrete legal obligations and entitlements that apply to listed products.

The Determination contains no penal provisions, no administrative sanctions and no enforcement mechanics. There is no express fine, criminal offence, administrative penalty or compliance regime set out in this instrument. The Determination’s content is classificatory: it identifies which drugs are "on F1" (Schedule 1) and which are "on F2" (Schedule 2) for the purposes of subsection 85AB(1) of the National Health Act 1953 (ss 6-7). Enforcement, penalties or compliance mechanisms, if any, will therefore depend entirely on the operative provisions of the Act and on any other statutory instruments or administrative rules that attach consequences to the F1/F2 status.

Key textual points from the Determination relevant to enforcement and penalties:

• Absence of sanctions in the instrument. Nowhere in the Determination text do the headings, operative sections, Schedules or endnotes specify contraventions, penalties, enforcement agencies, compliance notices, or review rights relating to breaches. The instrument is silent on enforcement.

• Reliance on the Act. Section 3 states the Determination is "made under section 85AB of the National Health Act 1953." Any regulatory teeth that follow from being listed as on F1 or F2 therefore derive from how the Act and associated regulations or policies treat those categories. The Determination itself does not create or define those treatments.

• Administrative practice and updates. The legislation history (Endnote 3) shows frequent amending determinations, which indicates an administrative regime that actively manages the lists. Administrative capability to add and remove items implies a decision-making and governance process; however, the Determination text does not include internal procedural safeguards, appeal routes or timelines for amendments. Such processes, if they exist, will be found in the Act, in separate administrative guidelines or in the amending instruments themselves.

• Implications for regulated parties. In practice, entities required to comply with statutory rules that depend on F1/F2 status will be exposed to whatever penalties or enforcement measures the Act and secondary instruments provide. Because the Determination supplies the canonical list, its contents will be used to determine whether a person or product falls within scope of those enforcement provisions.

• No litigation history recorded in the Determination. The instrument’s endnotes include a detailed legislation and amendment history, but do not record any judicial decisions or references to litigation challenging the Determination itself (see Endnote 3 and Endnote 4). The absence of litigation references in the compilation is not affirmative proof of no litigation, but the text provides no litigation record.

Practitioners must therefore look beyond this Determination when seeking the statutory penalties, enforcement options and review mechanisms that apply to conduct linked to the F1/F2 classifications. The Determination is the authoritative list; enforcement will stem from the Act’s substantive and procedural provisions and any delegated instruments that operationalise them.

This Determination operates exclusively by reference to a provision of the National Health Act 1953 and therefore interacts principally with that Act and any other legislative or administrative instruments that invoke the F1/F2 categories. The text offers limited direct cross-references, but the endnotes and authority clause provide clear pointers.

• Statutory basis: section 85AB of the National Health Act 1953. Section 3 states the instrument is "made under section 85AB of the National Health Act 1953." Sections 6 and 7 explicitly say the Schedules list drugs "for the purposes of subsection 85AB(1) of the Act." The Determination therefore functions as a subordinate instrument that populates a statutory list required by that subsection. Any statutory effects ascribed in other parts of the Act to the categories F1 or F2 will operate by reference to this instrument’s entries.

• Relationship to the Act’s scheme. The Determination does not restate or replicate other provisions of the Act. It is a registry-style instrument; to understand how a drug’s classification as "on F1" or "on F2" interacts with obligations, subsidies, procurement rules, or entitlements, one must read the relevant provisions of the National Health Act 1953. The Determination acts as an enabling factual annex to the Act: the Act provides substance, the Determination provides content.

• Interaction with amendment instruments and the Register. The legislation history (Endnote 3) lists numerous amending determinations by Register number and commencement date (for example, PB 45 of 2021 (F2021L00524) and many subsequent PB numbers). Each amending instrument modifies the Schedules. The compilation model and endnotes are produced under the Legislation Act 2003 framework for legislative instruments; editorial and presentational changes are also flagged (Endnote 1). The Register is the source for the current text and any uncommenced amendments are indicated in the endnotes.

• No express interaction with other statutes in the Determination. The instrument does not mention other Acts by name, nor does it purport to modify or displace provisions in other statutes. If other statutes reference the F1/F2 concepts, their practical interaction with this Determination will depend on how those statutes define or use the same terms. The Determination is silent on such cross‑statutory interactions.

• Administrative and procurement instruments. Given the nature of the lists,a long catalogue of pharmaceutical products and nutritional formulations,it is probable that administrative policies, procurement contracts, clinical guidelines and funding instruments will rely on the Determination as the canonical list. The Determination does not itself establish procurement rules or payments; it supplies the legal list those other instruments may reference.

• Editorial and legislative amendment framework. The compilation includes notes that editorial changes may be made under the Legislation Act 2003 and that amendments are documented in the endnotes (Endnote 1 and Endnote 4). Several references in Endnote 4 show provisions repealed or amended (for example, "s 2 rep LA s 48D"). Those matters reflect the interplay between instrument drafting practice and the Legislation Act 2003 machinery.

Practical consequence for users: to assess legal entitlements, duties and interplay with other laws, one must read this Determination in tandem with subsection 85AB(1), other relevant provisions of the National Health Act 1953, the series of amending determinations recorded in the endnotes, and any administrative guidelines or procurement instruments that reference the lists.

The Determination is not static. The endnotes provide detailed amendment and legislation history showing steady, periodic updates from 2021 through to 2026. The compilation front matter and Endnotes 3 and 4 are the instrument’s own record of amendments.

• Compilation metadata. The front matter states this is "Compilation No. 53" with a compilation date of 1 March 2026 and expressly notes "Includes amendments: F2026L00179." The compilation includes editorial notes, presentational changes and uncommenced amendments where applicable (see the "About this compilation" and Endnote 1).

• Chronology of registered amending instruments. Endnote 3 sets out a chronological table of each amending Determination with registration numbers, dates and commencement dates. The table begins with the original Determination registered 31 March 2021 (F2021L00390) which commenced 1 April 2021. It then lists a long series of amending determinations (PB numbers) with registration dates and the explicit commencement dates,nearly all amending instruments commence on the 1st of the month following registration. The entries continue at regular intervals, with instruments registered monthly or at short intervals through to 27 February 2026 (F2026L00179), with a commencement 1 March 2026 (Endnote 3).

• Scope of amendments. Endnote 4 provides a provision-level amendment history. It records that Schedule 1 was amended many times (entries show a long list of Register numbers F2021L00524 through F2026L00179). Schedule 2 also shows multiple amendments. The amendment history table indicates frequent changes to the Schedules themselves, while some other sections are shown as repealed or editorially changed under the Legislation Act 2003 (for example, "s 2 rep LA s 48D" and "s 4 rep LA s 48C" and "Schedule 3 rep LA s 48C").

• Editorial changes and the Legislation Act. The front material and endnotes note that editorial and presentational changes may have been made under the Legislation Act 2003 and that First Parliamentary Counsel may make presentational changes. Endnote 1 and the "Editorial changes" paragraph explain that such changes do not alter the effect of the law. The amendment history table indicates specific entries marked "ed C4", meaning editorial change C4 was applied.

• Practical cadence. The amendment record shows that the Schedules are actively managed and updated at frequent intervals,monthly at times. This cadence implies a standing administrative process for adding and removing items based on whatever criteria the Act and administering body use. The Determination itself does not describe the internal decision-making or consultation steps that produce these amendments; those processes would be described in the Act, in administrative guidelines, or in the amending instruments.

• How to track amendments. The Determination compilation and endnotes direct readers to the Register for full amendment details and to identify any uncommenced amendments. The front matter repeats that uncommenced amendments are noted in the endnotes and accessible via the Register.

For legal users, the amendment history is central: the legal identity of whether a product is on F1 or on F2 may change frequently, and the compilation records show that many items have been added across multiple amending determinations. Any compliance, procurement or clinical policy that depends on the lists must incorporate processes to monitor the Register and the frequent amending determinations recorded in Endnote 3.

The Determination compilation does not contain any entries describing litigation challenging the Determination or the lists. The endnotes provide a detailed legislative and amendment history, and they document editorial changes, repeals and amending instruments, but they do not catalogue court proceedings or judicial decisions that interpret or annul the Determination.

• No recorded judicial proceedings in the compilation. The text and the endnotes make no reference to judicial review proceedings, declaratory judgments, injunctions, or other litigation concerning the Determination. Endnote 3 and Endnote 4 are focused on administrative instrument registration and provision-level amendment history, not on case law.

• How to check for litigation. Because the compilation is a statutory instrument registry entry, absence of litigation references in the compilation does not preclude judicial review or case law that exists elsewhere. The Determination itself points users to the Register and to the Act but does not contain a litigation history. Practitioners seeking judicial treatment of the Determination or its interaction with the Act will need to search case law databases, administrative law reports and tribunal records; that search is outside the content of the instrument.

• Potential grounds for litigation (observational, not asserted). The Determination’s structure,long lists of discrete items without internal definitions of term‑scope (for example, strength, presentation, brand) and frequent amendments,creates predictable areas where disputes might arise in practice: whether a particular product, brand or strength falls within an entry; the lawfulness of an amendment process; procedural fairness in adding or removing items; and the consequences of misclassification for funding or regulatory entitlements. The instrument itself contains no judicial determinations addressing those issues.

• No references to appeals, merits review or internal review in the Determination. The instrument is silent on remedies or review pathways. Any review rights would derive from the parent Act or from general administrative law (for example, merits review tribunals or judicial review of decisions), none of which are described in the Determination’s text or endnotes.

In sum: the compilation contains no litigation history. If litigation has occurred, it is not reflected in the instrument’s endnotes. Practitioners requiring information on judicial interpretation, challenges to amendments, or remedies should consult external case-law databases and the relevant tribunal and court registers.

The Determination’s apparent simplicity masks several interpretive and practical risks that practitioners should notice. These "gotchas" derive from how the instrument is drafted, how frequently it is amended, and from the form of the Schedule entries. The text and endnotes supply the basis for all of the following points.

• The instrument classifies entries by wording, not by a detailed definitional matrix. The Schedules contain many entries expressed at differing degrees of specificity: single active ingredients (for example, "Abacavir" in Schedule 1), combination products ("Abacavir with Lamivudine" in Schedule 2), brand‑style compound descriptions, nutritional or medical formulas expressed as functional descriptions (for example, "Amino acid formula with carbohydrates, vitamins and minerals without phenylalanine"). Because only "Act" is defined in s 5, the scope of each Schedule entry depends on the literal list text. Users should not assume that an entry covers all strengths, salts, esters, routes of administration, generics or brand variants unless the Schedule wording clearly captures them.

• Near‑duplicates and related items on different schedules. The Schedules contain closely related entries placed in different categories. For example, "Abacavir" appears in Schedule 1, while "Abacavir with Lamivudine" is in Schedule 2. That pattern appears for other active ingredients and combinations. Parties that handle single active ingredients and combinations must check both Schedules; a combination product may be treated differently from its single‑ingredient counterpart.

• Formulation and nutritional descriptors create ambiguity. The Schedules include specialised nutritional formulas and protein/amino acid products described functionally rather than by precise product codes. Those items may be interpreted differently for procurement, supply or subsidy. The absence of strength, pack size or product code in the Schedule could create ambiguity if administrative rules or funding calculations require product-specific detail.

• No explicit treatment of generics, equivalents or biosimilars. The Schedules list drug names and product descriptions but do not explicitly state whether generic equivalents, different salts or biosimilar formulations fall within an entry. For biologics where brand, manufacturing process or presentation matter for regulatory pathways, that uncertainty can be consequential. Practitioners should not assume that a product outside the exact Schedule text is covered.

• Frequent amendments impose information maintenance costs. Endnote 3 shows a constant stream of amending determinations. If a party’s compliance or procurement processes rely on the Determination (as many will), they must implement timely monitoring and update systems. The amending instrument IDs and commencement dates are listed in the endnotes; failing to update to the current compilation could produce misalignment with the legal classification that applies on a given date.

• Interpretation disputes may require external sources. Because the Determination lacks interpretive rules (for example, no statement that Schedule entries are inclusive of "all salts, esters and preparations"), disputes about scope may require resort to the Act for administrative guidance or to administrative practice, or may give rise to interpretive litigation.

• No procedural detail for amendments contained in the Determination. The frequent amendments recorded in Endnote 3 are not accompanied in the Determination text by procedural descriptions of how items are added, how consultation is handled, or what review rights exist. Users cannot assume a particular consultation or merits review process from the Determination; the processes will be found in the Act or in separate administrative materials.

• Editorial changes may affect presentation but not substance. The compilation notes that First Parliamentary Counsel may make editorial and presentational changes under the Legislation Act 2003 (Endnote 1). Those changes are not supposed to alter legal effect, but users should be aware that presentational editing can change how entries are displayed even if they do not change legal coverage.

• Reliance on the Register for current text. The Determination explicitly directs readers to the Register for uncommenced amendments and for full amendment details. Failure to consult the Register risks reliance on out-of-date lists; the compilation date for this text is 1 March 2026 and it "Includes amendments: F2026L00179." Users must verify they are looking at the current version.

• No explicit cross-references to other schedules or regulatory codes. The instrument does not provide product codes, PBS item numbers or links to therapeutic classifications. Practitioners who need to map these entries to procurement systems or electronic health records will need to create their own crosswalks.

These are not conceptual criticisms but practical flags: the Determination’s brevity and list format drive a set of interpretive and operational requirements that organisations must manage if they depend on the lists for funding, procurement, clinical governance, or compliance.

The Determination itself imposes no procedural duties or reporting obligations. Compliance in this context therefore means aligning operational, procurement and clinical processes with the current authoritative lists so that statutory consequences under the National Health Act 1953 attach to the correct products. The measures below are practical steps grounded in the instrument’s text, the amendment history and the compilation notes.

• Read the Determination together with the Act. The Determination classifies products "for the purposes of subsection 85AB(1) of the Act" (ss 6-7). To understand what legal consequences flow from being on F1 or F2, consult subsection 85AB(1) of the National Health Act 1953 and any related provisions that reference F1/F2. The Determination is the factual input; the Act supplies the legal outputs. Compliance plans should therefore be drafted jointly against both instruments.

• Integrate the Schedules into internal master data. Because the Schedules are the canonical legal lists, businesses and agencies should import the Schedule entries into their master product lists, pharmacy information systems, procurement catalogs and contracting systems. Given the list format, implement field mappings that capture the literal Schedule text, and note where Schedule wording is functional (for example, nutritional formulations) rather than a simple active ingredient name.

• Monitor the Register and the amendment history. The endnotes show a continuous sequence of amendments (Endnote 3). Establish an alerting process to monitor the Federal Register of Legislation (the "Register") and the specific PB numbers and Register IDs listed in the Determination’s endnotes. Note that most amendment determinations commence on the 1st of a month; design updates to align with amendment commencement dates.

• Maintain audit trails for classification changes. Because amending determinations will add and remove entries, maintain dated records of which version of the Schedules was relied on at any time. This is important for funding, reimbursement, supply contracts and clinical governance, where legal classification at a specific time matters. The compilation date and the included amending instrument IDs (e.g., "Includes amendments: F2026L00179") should be recorded in your audit trail.

• Map Schedule entries to commercial codes and strengths. The Schedule entries do not consistently specify strength, route, or pack size. Create an internal mapping between Schedule text and the commercial product identifiers you use (ATC codes, PBS item numbers, product codes, GTINs). Where ambiguity exists (for example, whether a generic or different salt is captured by the entry), document assumptions and, where necessary, seek administrative clarification from the responsible agency under the Act.

• Treat combinations differently from single ingredients. The Schedules contain items that are combinations and place some combinations in a different schedule from their component ingredients (for example, "Abacavir" in Schedule 1, "Abacavir with Lamivudine" in Schedule 2). Ensure procurement, reimbursement and clinical decision supports are configured to evaluate both single-ingredient and combination products against both Schedules so as not to misclassify coverage or entitlements.

• Ask for administrative clarification where scope is unclear. The Determination contains no interpretive rules and no contact points. Where a product’s inclusion is unclear (for example, whether a biosimilar, salt, or ester is captured), seek written administrative confirmation from the agency that administers the Act or rely on administrative guidance documents that the agency publishes. Document any advice received.

• Update clinician and pharmacy guidance and IT systems promptly. Given the practical implications for prescribing and dispensing, update clinical guidelines, electronic prescribing rules and pharmacy dispensing systems when the Schedules change. Because many amendments commence on scheduled dates (see Endnote 3), coordinate system deployments and clinician communication with amendment commencement dates.

• Consider contractual implications. Contracts for supply, reimbursement and funding that reference F1 or F2 status should either reference the Determination dynamically (for example, by referencing the current Determination on the Register at the time of supply) or include specific clauses that address changes in classification and amendment mechanics. Draft change-management provisions to handle the frequent updates recorded in the amendment history.

• Keep legal and compliance teams engaged. The Schedules and their amendment cadence create ongoing legal‑compliance obligations to maintain up-to-date classifications. Ensure legal and compliance teams have processes to receive amendment notifications, update internal reference libraries, and provide advice on the consequences of particular changes.

• Verify compilation dates in documentation. When relying on the Determination in legal opinions, procurement files or funding validations, record the compilation number (here, Compilation No. 53) and the compilation date (1 March 2026) and the included amendment IDs to show which version you used.

These steps do not arise from duties spelled out in the Determination text; they are practical measures required to align operations with the legal classification the Determination supplies. The Determination is a content instrument: compliance therefore means keeping your operational content, systems and processes aligned with the current Schedules and with the legal framework of the National Health Act 1953.

This section provides a focused recapitulation and analysis of the amendment record as reproduced in the instrument’s endnotes. The Determination’s endnotes (Endnote 3 and Endnote 4) give a detailed, itemised history of registration and commencement of the original instrument and of subsequent amending determinations. The pattern is relevant for any user who must maintain legal, clinical or procurement alignment.

• Original registration and commencement. The National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021) was registered on 31 March 2021 (F2021L00390) and commenced on 1 April 2021 (Endnote 3).

• Frequent, structured amending determinations. Endnote 3 lists successive amending determinations, usually by month, each with a PB number, Register ID and an explicit commencement date (most commonly the 1st day of the following month). Examples include PB 45 of 2021 (F2021L00524) registered 30 April 2021, commenced 1 May 2021; PB 54 of 2021 (F2021L00657) registered 28 May 2021, commenced 1 June 2021; and so on through PB 23 of 2026 (F2026L00179) registered 27 February 2026 and commenced 1 March 2026. The history shows many amending determinations across 2021-2026, indicating an active program of updates (Endnote 3).

• Provision-level amendment history. Endnote 4 shows how specific provisions of the Determination were affected. Schedule 1 has a long sequence of amendments annotated with the Register IDs of the amending instruments. Schedule 2 likewise has many amending entries. Some other minor provisions or numbered sections are shown as repealed or editorially changed in line with the Legislation Act 2003. The amendment history table supplies granular mapping between amendment instruments and the parts of the Determination they altered (Endnote 4).

• Editorial changes flagged. Endnote 1 (Editorial changes) and Endnote 4 note that certain editorial changes were applied under the Legislation Act 2003 and that First Parliamentary Counsel may make presentational changes to the compilation. The endnotes indicate that such changes are intended not to alter legal effect but to improve navigability and consistency of presentation.

• Uncommenced amendments and register access. The compilation foreword warns that any uncommenced amendments are not reflected in the running text and are accessible on the Register; the endnotes indicate where uncommenced amendments appear underlined in the endnotes. Users must check the Register for the full amendment picture (see the "About this compilation" section and Endnote 1).

• Practical cadence for operational systems. The steady flow of amending determinations suggests agencies and regulated parties should expect monthly or regular updates. The amending instruments are discrete legislative instruments (PB numbers with Register IDs) and each comes with a clear commencement date; that structure allows organisations to align their update processes to the legal commencement timetable.

• How the amendment history should be used. In legal opinions, procurement decisions and clinical governance, cite the exact Register ID and commencement date of the amending determination that produced the classification being relied upon. The compilation provides the necessary citation models (for example, F2026L00179 commenced 1 Mar 2026).

In summary: the Determination is subject to continuous amendment through distinct legislative instruments. The endnotes supply the necessary register references and commencement dates; users must reference those amending instruments when determining which version of the Schedules applied at any given time.

The compilation does not record litigation concerning the Determination. The endnotes and legislation history contain detailed records of registration and amendment of the Determination and its Schedules, but they contain no references to judicial or tribunal decisions interpreting, quashing or otherwise adjudicating the Determination or its effects. The instrument therefore provides no internal litigation narrative. For practitioners who need to know whether courts or tribunals have considered the Determination, the following practical points apply.

• No litigation entries in the compilation. Neither the main text nor the endnotes record court decisions or tribunal determinations dealing with the validity, interpretation or application of this Determination. The endnotes focus exclusively on administrative amendment and compilation metadata (Endnotes 1-4).

• Searching external sources is necessary to find case law. The absence of litigation references in the compilation does not establish there has never been litigation; it simply means the compilation does not document any. Practitioners should search authoritative case-law databases, tribunal registries and judicial reports for potential challenges under administrative law (for example, judicial review of amendment processes) or disputes over the classification of particular products.

• Predictable litigation themes. Based on the instrument’s form, litigation challenges, where they occur, are likely to cluster around a few themes: (a) whether a particular product or strength falls within a Schedule entry; (b) whether the administrative process for adding/removing items complied with statutory procedural requirements (if any); (c) whether a change in classification had legally flawed procedural or merits bases that affected entitlements or funding; and (d) disputes about the retrospective application of amendments. The Determination itself contains none of the procedural material needed to resolve such claims; those matters would be governed by the Act and by administrative practice or separate instruments.

• No internal review or appeal information in the Determination. The instrument contains no information on review rights, merits review avenues or appeal processes for parties affected by Schedule entries or by amendments. Any statutory review rights must be located in the National Health Act 1953 or in ancillary legislation or policy.

• Litigation risk for absent interpretive rules. The Schedules’ lack of consistent detail about strength, salt, route or brand may give rise to interpretive disputes in practice. Parties should therefore preserve records of administrative communications and, where possible, seek written clarification from the administering agency before taking action where classification is unclear.

Conclusion for users: consult external legal databases to discover any litigation. The Determination’s compilation is silent on court or tribunal engagement; practical compliance strategies should therefore assume the possibility of interpretive disputes and adopt documentation and clarification practices accordingly.

This second "Gotchas" section highlights additional, specific practical traps that arise from the content, structure and amendment pattern of the Determination. These are operational and interpretive points drawn directly from the instrument’s text, Schedules and endnotes.

• Literalism trumps intuition. Because the Schedules are the legal source for whether an item is on F1 or F2 (ss 6-7), the literal wording of a Schedule entry controls. Do not assume broader coverage by reference to trade names, pharmacopoeial conventions, or industry shorthand. For example, "Insulin neutral" appears in Schedule 1; whether a particular product marketed under a brand that uses a different INN or presentation is captured will depend on whether the brand name appears or whether administrative guidance treats it as covered.

• Discrete handling of combination products. Products that are combinations are listed separately from their components. That means a supply chain or pharmacy software that maps only by active ingredient may misclassify a combination product unless it accounts for separate Schedule entries.

• Nutritional, formula and medical food entries require careful mapping. Many Schedule entries are nutritional or formula descriptions, such as "Amino acid formula with vitamins and minerals without phenylalanine" or "Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids...". These items will not map neatly to conventional drug databases and may require bespoke coding and clinical classification.

• Reconciliation with external coding systems. The Schedules do not supply ATC codes, PBS item numbers or GTINs. Organisations that need to integrate the Determination into electronic systems must construct a mapping table and keep it updated with each amending determination.

• Operational timing mismatch. Amendments often register before their commencement dates. The endnotes show that an amending determination is registered on one date and commonly commences the next. Organisations must be keyed to the commencement date, not merely the registration date, when aligning operations and communications.

• Potential for temporary coverage gaps. If a product is removed from one Schedule and only later added to another or to an alternative funding instrument, there may be periods where legal classification is uncertain. Maintain contingency processes for such transitions.

• Absence of listed contact points or explanatory material. The Determination does not provide agency contact information, policy rationale or explanatory notes about the reasons for additions or removals. Those materials, if they exist, will be in separate administrative publications or in the amending instrument's explanatory material on the Register.

• Version control in clinical guidance. Clinical guidelines and formularies that reference F1/F2 status should specify the version of the Determination they use. Because the lists are amended frequently, version control is essential to prevent mismatches between clinical policy and statutory classification.

• Beware of assumptions about equivalence. The presence of a product name in a Schedule does not automatically indicate that all presentations marketed under that name are treated identically; strength, presentation and route differences may matter. Seek administrative confirmation where necessary.

These are practical hazards for implementers and legal advisers. The Determination’s brevity and active amendment record call for deliberate data governance, version control and administrative liaison.

This second "How to comply" section sets out a concise operational checklist and risk-management steps. It reiterates and codifies prior practical suggestions into an implementable compliance plan aligned with the instrument’s structure and amendment record.

1. Map legal effect first. Begin by identifying which provisions of the National Health Act 1953 rely on the F1/F2 classifications. The Determination (ss 6-7) is a list; the legal consequences are in the Act. Produce a legal memo that records the statutory consequences for being on F1 or F2 and how those consequences affect your organisation.

2. Import and version the Schedules. Load the text of Schedule 1 and Schedule 2 into your master product registry exactly as worded in the Determination. Record the compilation number (Compilation No. 53), compilation date (1 March 2026) and the specific Register ID(s) included (for example, F2026L00179). Maintain a version history tied to the Register IDs recorded in Endnote 3.

3. Set up automated monitoring of the Register. Because the instrument has numerous amendments (Endnote 3), implement an automated watch on the Federal Register of Legislation for new amending determinations (PB numbers and Register IDs) affecting this Determination. Configure notifications for registration and for commencement dates.

4. Create a Schedule-to-product crosswalk. Map each Schedule entry to your internal product identifiers (GTINs, catalogue codes, PBS numbers, ATC codes). Where an entry is ambiguous, flag it for legal review and seek written administrative clarification.

5. Update clinical and pharmacy systems promptly. On each amendment’s commencement date, update electronic prescribing rules, pharmacy dispensing checks, procurement lists and stock systems. Coordinate with IT teams to schedule deployments that match amendment commencement dates, not just registration dates.

6. Document interpretive assumptions. For entries where scope is unclear (e.g. generic equivalents, salts, strengths), make and record interpretive assumptions, and where appropriate seek written confirmation from the administering agency. Preserve that correspondence in compliance files.

7. Amend contracts and service agreements. For supply contracts, reimbursement arrangements and tenders that reference F1/F2 status, revise clauses to reference the Determination dynamically and to set out processes for changes following amending determinations. Include transition clauses for classification changes.

8. Educate clinical and procurement staff. Provide training or briefings to clinicians, pharmacists and procurement staff on the significance of F1/F2 classifications, the literal nature of the Schedules, and the need to check the Register for amendments.

9. Maintain audit and evidence trails. Keep dated records of which version of the Schedules applied when, the internal mapping used for decisions, and any administrative advice received. This will be important if disputes arise over coverage or entitlement.

10. Engage legal counsel for borderline cases. If a product’s inclusion or removal has material financial or clinical consequences, obtain formal legal advice and consider formal review options under the Act or administrative law avenues if there is reason to contest an amendment process.

11. Keep an eye on related administrative material. Look for agency guidance, explanatory memoranda to the amending determinations, or policy statements that explain the practical operation of the lists. Those materials may appear on the Register linked to the amending instrument.

12. Plan for operational contingencies. Because removals or reclassifications can change funding or supply obligations, build business continuity plans that can rapidly adapt to classification changes, especially for high‑cost or time‑sensitive therapies.

Following this checklist aligns institutional processes to a Determination that is a statutory list with frequent updates. The core compliance task is information governance: ensuring the current governmental classification is reflected in clinical, procurement and legal systems, and documenting how each decision was made on the basis of the applicable version of the Determination.